Evidano home
Commentary on News

AI Qualitative Analysis of Hepatitis C Barriers

Evidano7 min read

Public health researchers need to connect treatment-access statistics with the lived experiences behind those statistics. The November 20, 2026 PLOS One study on Los Angeles County shows how mixed-methods research can identify both the prevalence of Hepatitis C treatment barriers and the reasons patients delay care. This article explains the study's findings and shows how AI qualitative analysis of hepatitis C treatment barriers can help research teams organize interviews, compare participant segments, and translate themes into actionable interventions. The discussion is research-focused and non-diagnostic.

Key Takeaways

The PLOS One study, published on November 20, 2026, found that Hepatitis C treatment access in Los Angeles County was limited by interacting personal, provider, insurance, language, transportation, and healthcare-navigation barriers. The study combined program data from 344 case-residents with thematic analysis of interviews involving 10 participants.

  • According to the PLOS One study, 54% of 344 case-residents contacted between October 2024 and January 2025 reported barriers to Hepatitis C treatment.
  • According to the PLOS One study, among 91 case-residents who reported specific barriers, personal barriers represented 43%, provider-related barriers represented 31%, insurance barriers represented 13%, and inadequate medical access represented 13%.
  • According to the PLOS One study, the qualitative sample included 7 untreated participants and 3 treated participants, with interviews conducted in English and Spanish.
  • According to the PLOS One study, key facilitators included personal motivation, family and community support, trust in providers, adequate insurance, understanding treatment benefits, and the desire to avoid stigma.
  • According to the PLOS One study, potential responses include language support, patient navigation, mobile clinics for people experiencing homelessness, continuity of care after incarceration, and reduced insurance restrictions.

What the Hepatitis C Access Study Measured

The PLOS One research team used a convergent parallel mixed-methods design from October 2024 through January 2025 to study why Los Angeles County residents diagnosed with Hepatitis C did or did not access treatment. The quantitative component used de-identified program data, while the qualitative component used semi-structured interviews to explain how and why reported barriers affected treatment decisions.

The PLOS One study analyzed program data from 344 case-residents contacted by the Los Angeles County Department of Public Health. The study also used thematic analysis of interviews with 10 participants, including 7 untreated participants and 3 treated participants.

The PLOS One researchers used descriptive frequencies and percentages for the quantitative data because most specific barrier categories had fewer than 15 observations. The research team used inductive coding, iterative theme refinement, independent transcript coding, and meetings to resolve coding discrepancies for the qualitative data.

The PLOS One study was limited by the small qualitative sample, the uneven distribution between treated and untreated participants, and the absence of inferential modeling across race, language, or insurance groups. The authors describe the qualitative findings as exploratory rather than broadly generalizable.

Hepatitis C Treatment Barriers: Findings Snapshot

Date or periodMeasureValueResearch implication
October 2024 to January 2025Case-residents contacted344Program data provided the quantitative base for the mixed-methods analysis.
October 2024 to January 2025Case-residents reporting barriers54%More than half of the contacted population reported at least one treatment-access barrier.
October 2024 to January 2025Specific-barrier respondents91Barrier categories were compared using descriptive statistics.
October 2024 to January 2025Most common barrier categoryPersonal barriers, 43%Individual circumstances and treatment priorities were central to access challenges.
October 2024 to January 2025Provider-related barriers31%Provider communication, follow-up, and navigation influenced treatment access.
October 2024 to January 2025Qualitative interview participants10, including 7 untreated and 3 treatedInterviews added context to the quantitative categories.
November 20, 2026Study publicationPLOS One, volume 21, issue 11The findings were reported in a peer-reviewed, open-access research article.

Implications for Public Health and Healthcare Researchers

Public health teams should analyze treatment barriers as connected patient, provider, and system-level experiences rather than as isolated categories. The PLOS One study found that homelessness, incarceration, drug addiction, language barriers, long waits, cost, transportation, limited information, and difficulty navigating care could overlap across treatment journeys.

Language-sensitive qualitative analysis is especially important for programs serving multilingual communities. One untreated Spanish-speaking participant told the PLOS One researchers, "Since I don’t speak 100% English, I was treated at the hospital in Los Angeles and one doctor was a liver doctor, the other one was a hepatitis doctor, the other one was a cirrhosis doctor, and I didn’t understand very well what they were telling me."

Patient education and trust can operate as treatment facilitators when research findings are translated into outreach messages. An untreated Spanish-speaking participant told the PLOS One researchers, "Because, well yes, I have [HCV which] is going to make me sick in the future or I can pass [it] on to someone else. I think it is good to [seek treatment]."

AI-assisted qualitative research can support this work by making recurring themes easier to identify across transcripts, comparing treated and untreated participants, and surfacing differences between English- and Spanish-language accounts. Human researchers must still review interpretations, protect participant confidentiality, and avoid treating automated themes as clinical diagnoses or causal proof.

How Evidano Supports AI Qualitative Analysis of Hepatitis C Barriers

Problem: Researchers need to connect statistics with patient explanations

Evidano is an AI-powered qualitative data analysis platform that helps researchers analyze interviews, open-ended surveys, and documents.

Evidano can organize interview transcripts and research documents into thematic, frequency, and cross-segment analyses, helping teams compare quantitative barrier categories with participant narratives. Researchers can learn more about the platform's capabilities on the Evidano features page.

Problem: Multilingual interviews can hide important access themes

Evidano supports transcription and translation workflows with custom dictionaries, which can help research teams standardize domain-specific terms before reviewing themes.

The PLOS One study conducted interviews in English and Spanish, making language-aware review relevant to the study population. Researchers should validate translated meaning against the original recordings or transcripts before reporting findings.

Problem: Segment differences are difficult to review consistently

Evidano supports cross-segment analysis, allowing researchers to organize comparisons such as treated versus untreated participants, English versus Spanish interviews, or provider-related versus personal barriers.

Evidano also provides visualizations such as word clouds, co-occurrence networks, and hierarchical codes with subcodes, which can help teams inspect relationships among themes while retaining human oversight.

Problem: Sensitive health data requires careful handling

Evidano provides transcription with PII redaction and encrypted data handling, while stating that customer data is never used to train third-party models. Public health and healthcare researchers should still follow institutional review board requirements, consent terms, data-minimization practices, and applicable privacy policies.

The PLOS One study de-identified interview data by removing identifying information and assigning participant IDs, illustrating why privacy controls should be part of the qualitative workflow from collection through reporting.

FAQ: AI Qualitative Analysis of Hepatitis C Treatment Barriers

What did the 2026 Los Angeles County Hepatitis C study find?

The 2026 PLOS One study found that 54% of 344 case-residents reported barriers to Hepatitis C treatment between October 2024 and January 2025.

The study identified personal, provider-related, insurance, transportation, language, information, housing, incarceration, and healthcare-navigation barriers, alongside facilitators such as motivation, social support, provider trust, and insurance coverage.

Why did the researchers combine quantitative and qualitative analysis?

The researchers combined quantitative and qualitative analysis because program data showed how often barriers were reported, while interviews explained why those barriers affected treatment decisions.

The PLOS One study used 344 case-residents for the quantitative component and 10 interview participants for the qualitative component.

How can AI help analyze Hepatitis C treatment interviews?

AI can help researchers transcribe, translate, code, summarize, and compare large collections of Hepatitis C treatment interviews, but human researchers must validate the resulting themes.

A platform such as Evidano can support thematic, frequency, and cross-segment analysis while helping teams review differences between treated and untreated participants or between language groups.

What are the main limitations of AI qualitative analysis in public health?

The main limitations are potential misinterpretation, translation loss, coding bias, privacy risk, and overclaiming from small or unrepresentative samples.

The PLOS One authors described their qualitative findings as exploratory because the interview sample included only 10 participants and was unevenly distributed between treated and untreated groups.

Is this Hepatitis C research medical advice?

This article is a research-focused interpretation of a peer-reviewed study, not medical advice or a diagnostic tool.

Healthcare decisions should be made with qualified medical professionals and should not be based on automated qualitative analysis alone.

Conclusion and Next Steps for Hepatitis C Qualitative Research

The November 20, 2026 PLOS One study demonstrates how mixed-methods research can connect the scale of Hepatitis C treatment barriers with the lived experiences behind them. AI qualitative analysis can help public health researchers process interviews faster, compare segments more systematically, and identify themes related to language, trust, cost, navigation, and social support. Human review, ethical safeguards, and careful interpretation remain essential, especially when research involves sensitive health information and small samples. Teams that want to apply this workflow can try Evidano for free.

Topics

  • AI qualitative analysis of hepatitis C treatment barriers
  • qualitative analysis of healthcare barriers
  • Hepatitis C treatment access research
  • AI thematic analysis public health
  • mixed-methods healthcare research

Keep reading

Browse all articles